Patient enrollment completed for first of two Phase 3 trials for SCH 530348 for acute coronary syndrome (ACS)
Merck announced the completion of patient enrollment for its Phase 3 Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2˚P-TIMI 50) trial, one of its two Phase 3 studies of SCH 530348 for the treatment of acute coronary syndrome (ACS).
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.